-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The new study found that more than half of the blood cancer patients who were vaccinated twice had little protection against COVID-19
The data from the SOAP-02 trial was published today in a letter to Cancer Cell, investigating the level of immune protection of 159 participants (128 of whom were cancer patients) after Pfizer’s delayed increase in the vaccine dose
These data highlight the vulnerability of patients with bleeding cancer to COVID-19
Patients with solid cancers, such as breast cancer, urology, or skin cancer, also respond poorly to a single dose of the vaccine, with a seroconversion rate of only 38%
Although previous research believes that delaying the second vaccine injection in healthy controls can improve the immune response that has already formed, this new research shows that this does not apply to cancer patients
The trial was led by an inter-institutional collaboration between King's College London and the Francis Crick Institute, and was supported by the Cancer Institute UK
The authors of the study urge these vulnerable groups to be protected by continuing to wear masks, maintaining social distancing in crowded areas such as public transportation, and vaccinating school-age children who may come into contact with blood cancer patients or other high-risk groups
The lead author of the study, Dr.
Lead author Professor Adrian Heidi from King’s College London and the Francis Crick Institute said: “The SARS-CoV-2 vaccine has achieved extraordinary success, but not everyone has achieved success
Professor Charles Swanton, Chief Clinician of the Cancer Institute UK, said: “This study shows that, despite being vaccinated twice, more than half of blood cancer patients still fail to develop an antibody response to SARS CoV2.
"A growing body of evidence shows that despite being vaccinated, patients with blood cancer are still vulnerable during the COVID-19 pandemic.
"As the world begins to return to normal, we must not forget vulnerable patients like this.
DOI
https://doi.
Article title
Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer
